Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 2/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.38 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | THRB | P10828 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | PARP1 | P09874 | 1/20 | 0.37 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.37 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | DTYMK | P23919 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4005175 | 0.85 | NR1H2 (0.41) | NR1H2USP2SMN1; SMN2ESR2TP53 | |
| SCHEMBL1583253 | 0.85 | P2RX7 (0.46) | NR1H2USP2SMN1; SMN2ESR2TP53 | |
| SCHEMBL24744821 | 0.83 | NR1H2 (0.40) | NR1H2USP2SMN1; SMN2ESR2TP53 | |
| SCHEMBL1176507 | 0.83 | NR1H2 (0.40) | NR1H2USP2SMN1; SMN2ESR2TP53 | |
| SCHEMBL4390630 | 0.83 | NR1H2 (0.41) | NR1H2USP2SMN1; SMN2ESR2TP53 | |
| SCHEMBL12495387 | 0.82 | ITGB3 (0.41) | NR1H2USP2SMN1; SMN2GPR119ESR2 | |
| SCHEMBL1583540 | 0.82 | CNR2 (0.40) | NR1H2USP2SMN1; SMN2ESR2MAPT | |
| SCHEMBL6969188 | 0.82 | P2RX7 (0.49) | NR1H2USP2SMN1; SMN2ESR2TP53 | |
| SCHEMBL4388222 | 0.81 | GPR119 (0.41) | NR1H2GPR119ESR2MAPTALDH1A1 | |
| SCHEMBL3635546 | 0.81 | P2RX7 (0.45) | NR1H2USP2SMN1; SMN2ESR2TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110494431-B | Azacyclo derivative, preparation method and medical application thereof | 苏州浦合医药科技有限公司 | 2022-11-04 | — | — | CN | disclosed |
| CN-107098886-B | Prazinone-containing quinazolinone PARP-1/2 inhibitor and preparation method, pharmaceutical composition and application thereof | 中国医学科学院药物研究所 | 2020-07-14 | — | — | CN | disclosed |
| CN-110494431-A | Nitrogen heterocycles derivative, preparation method and its medical usage | BEIJING YUEZHIKANGTAI BIOMEDICINES CO LTD | 2019-11-22 | — | — | CN | disclosed |
| WO-2019062657-A1 | NITROGEN HETEROCYCLIC DERIVATIVE, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL USE THEREOF | 北京越之康泰生物医药科技有限公司 | 2019-04-04 | — | — | WO | disclosed |
| US-20090306133-A1 | New Acetyl Coenzyme A Carboxylase (ACC) Inhibitors And Uses In Treatments Of Obesity And Diabetes Mellitus - 087 | ASTRAZENECA AB (SE) | 2009-12-10 | — | — | US | disclosed |
| US-20090306133-A1 | New Acetyl Coenzyme A Carboxylase (ACC) Inhibitors And Uses In Treatments Of Obesity And Diabetes Mellitus - 087 | ASTRAZENECA AB (SE) | 2009-12-10 | — | — | US | disclosed |
| US-20090306133-A1 | New Acetyl Coenzyme A Carboxylase (ACC) Inhibitors And Uses In Treatments Of Obesity And Diabetes Mellitus - 087 | ASTRAZENECA AB (SE) | 2009-12-10 | — | — | US | disclosed |
| WO-2009082346-A1 | NEW ACETYL COENZYME A CARBOXYLASE (ACC) INHIBITORS AND USES IN TREATMENTS OF OBESITY AND DIABETES MELLITUS - 087 | ASTRAZENECA AB (SE) | 2009-07-02 | — | — | WO | disclosed |
| WO-2009082346-A1 | NEW ACETYL COENZYME A CARBOXYLASE (ACC) INHIBITORS AND USES IN TREATMENTS OF OBESITY AND DIABETES MELLITUS - 087 | ASTRAZENECA AB (SE) | 2009-07-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306133-A1 | New Acetyl Coenzyme A Carboxylase (ACC) Inhibitors And Uses In Treatments Of Obesity And Diabetes Mellitus - 087 | ACACA, ACACB, ACAT1 | NR1H2 653/4885USP2 3078/4885SMN1; SMN2 4702/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.